title: Liposarcoma in the oral and maxillofacial region: an analysis of 10 consecutive patients.
abstract: Ten consecutive patients with liposarcoma in the oral and maxillofacial region were analyzed retrospectively. Contrary to the majority of previous reviews, a female preponderance (two males and eight females) and younger incidence peak age (33 years) were found. Tumor sites were face (three), parotid (three), oral cavity (two), and mandible (two). Using a current histologic system, seven patients were classified as myxoid, and three as well-differentiated, round-cell, and pleomorphic lesions, respectively. Three patients died of recurrent disease 7 months, 20 months, and 4 years, respectively, after treatment; one patient died of metastatic liver and lung lesions and six patients remain free of disease (2 to 3 years). Clinical and histologic features, tumor behavior, treatment options, and patient prognosis are discussed and the literature is reviewed.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Shandong Medical University, Jinan, People's Republic of China.
authors.forename: J W
authors.initials: JW
authors.lastname: Zheng
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D005153:Facial Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007573:Jaw Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D008080:Liposarcoma / Q000453:epidemiology* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D018208:Liposarcoma, Myxoid / Q000453:epidemiology / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate